disulfiram (antabuse) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Disulfiram is a carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake causing an accumulation of acetaldehyde in the blood producing highly unpleasant symptoms. Disulfiram blocks the oxidation of alcohol through its irreversible inactivation of aldehyde dehydrogenase, which acts in the second step of ethanol utilization. In addition, disulfiram competitively binds and inhibits the peripheral benzodiazepine receptor, which may indicate some value in the treatment of the symptoms of alcohol withdrawal, however this activity has not been extensively studied. Used for the treatment and management of chronic alcoholism.   NCATS

Chemistry

  • SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC
  • InChIKey: AUZONCFQVSMFAP-UHFFFAOYSA-N
  • Mol. Mass: 296.539
  • ALogP: 3.62
  • ChEMBL Molecule:
    disulfiram  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1.0101 - $1.7719
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,1'-dithiobis(n,n-diethylthioformamide) | ant-1403 | antabuse | antabuse (tn) | bis(diethylthiocarbamoyl) disulfide | disulfiram | esperal | n,n,n',n'-tetraethylthiuram disulfide | nsc-25953 | ora102 | tetraethylthioperoxydicarbonic diamide | tetraethylthiram disulfide | tetraethylthiuram disulfide | tetraethylthiuram disulphide

Organizations (81)

Research & Development (69)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (30)

Approved Indications (1)


 

Alcoholism (approved 1981)

Experimental Indications - Clinical Trial Phases 1-4 (30)


 

Alcohol-Induced Disorders (Phase 1/Phase 2)

Alcoholism ()

Alcohol-Related Disorders (Phase 2)

Analgesics, Opioid (Phase 2)

Anxiety Disorders (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2/Phase 3)

Cocaine-Related Disorders (Phase 4)

COVID-19 (Phase 2)

Fatigue (Phase 1/Phase 2)

Glioblastoma (Phase 2/Phase 3)

Glioma (Phase 2/Phase 3)

HIV (Phase 1/Phase 2)

HIV Infections (Phase 1/Phase 2)

Hyperhidrosis (Phase 2)

Machiavellianism (Phase 1)

Macular Degeneration (Phase 1/Phase 2)

Melanoma (Phase 2)

Methamphetamine (Phase 1/Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Obesity (Early Phase 1)

Opioid-Related Disorders (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Quality of Life (Phase 1/Phase 2)

Retina (Phase 1/Phase 2)

Sarcoma (Phase 1)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial Organizations: 69

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue